Prevalence and risk factors associated with pain 21 months following surgery for breast cancer

Moloney, Niamh; Sung, Jennie; Kilbreath, Sharon L.; Dylke, Elizabeth

doi:10.1007/s00520-016-3292-1

Cited by 25 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Globally, breast cancer surgery is one of the most common surgeries among the female population [1]. Nearly half of the patients suffer chronic pain following breast cancer surgery, and 24% of the patients categorize their pain as moderate to high [2]. There are several risk factors for chronic postoperative pain.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the efficacy of erector spinae plane block performed with different concentrations of bupivacaine on postoperative analgesia after mastectomy surgery: ramdomized, prospective, double blinded trial

et al. 2019

View full text Add to dashboard Cite

Background Breast cancer surgery is one of the most common surgeries among the female population. Nearly half of the patients suffer chronic pain following breast cancer surgery, and 24% of them categorizing their pain as moderate to high. In this study, effects of ultrasound-guided erector spinae plane (ESP) block performed using two different concentrations of bupivacaine on postoperative tramadol consumption, pain scores, and intraoperative fentanyl requirements among patients who underwent radical mastectomy surgery were compared. Methods This double-blinded, prospective, and randomized study included patients with age ranged 18–70, American Society of Anesthesiologist physical status I–II, and scheduled for unilateral modified radical mastectomy surgery. The patients were randomly allocated into two groups. In group I, ESP block was performed with 0.375% bupivacaine. In group II, ESP block was performed with 0.25% bupivacaine. General anesthesia was induced in both groups according to the standard procedures. When the pain score was ≥4, patients received intravenous (i.v.) 25 mcg fentanyl in the recovery room or 4 mg of morphine in the surgical ward as a rescue analgesia. The main measurements were postoperative tramadol consumption; Numerical Rating Scale (NRS) scores 15, 30, and 60 min and 12 and 24 h postoperatively; and intraoperative fentanyl requirements. Results In total, 42 patients (21 patients in each group) were included in the study. The mean tramadol consumption at the postoperative 24th h was 149.52 ± 25.39 mg in group I, and 199.52 ± 32.78 mg in group II ( p = 0.001). In group I, the NRS scores were significantly lower at every time points compared with those in group II. The mean intraoperative fentanyl requirement was similar in the two groups. Conclusion Although ESP block performed with both concentrations of bupivacaine provided effective postoperative analgesia, the higher concentration of bupivacaine significantly reduced postoperative tramadol consumption after radical mastectomy surgery. Clinical trial registration The study was registered prospectively with the Australian New Zealand Clinical Trials Registry (trial ID: ACTRN12618001334291at 08/08/2018).

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of the efficacy of erector spinae plane block performed with different concentrations of bupivacaine on postoperative analgesia after mastectomy surgery: ramdomized, prospective, double blinded trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Fortunately, advances in treatment strategies and early diagnosis due to the improved screening and detection techniques have increased the 5‐year survival rates . Although surveillance for cancer recurrence is the number 1 priority during follow‐up visits, one should be aware that a significant proportion of survivors are affected with complications, such as pain, with prevalence ranging from 11% to 50% . Approximately 30% of breast cancer survivors (BCS) experience above‐average pain up to 10 years after the end of treatment …”

Section: Introductionmentioning

confidence: 99%

“…1,2 Although surveillance for cancer recurrence is the number 1 priority during follow-up visits, one should be aware that a significant proportion of survivors are affected with complications, such as pain, with prevalence ranging from 11% to 50%. [3][4][5][6][7] Approximately 30% of breast cancer survivors (BCS) experience above-average pain up to 10 years after the end of treatment. 8 Bokhari et al 7 stated that the additional suffering from persistent pain can be physically and psychologically overwhelming for women who were already confronted with the diagnosis of breast cancer and who attempted to cope with the various treatment regimens.…”

Section: Introductionmentioning

confidence: 99%

Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain?

et al. 2018

View full text Add to dashboard Cite

Introduction The differentiation between acute and chronic pain can be insufficient for appropriate pain management. The aim of this study was to evaluate the prevalence of the predominant pain type (nociceptive, neuropathic, or central sensitization [CS] pain) in breast cancer survivors (BCS) with chronic pain. The secondary aims were to examine (1) differences in health‐related quality of life (HRQoL) between the different pain groups; and (2) the associations between patient‐, disease‐, and treatment‐related factors and the different pain types. Methods To determine the prevalence of the predominant type of pain, a recently proposed classification system was used. BCS were asked to complete the VAS for pain, Douleur Neuropathique 4 Questionnaire, Margolis Pain Diagram, Central Sensitization Inventory, and Short Form 36 (SF‐36). Results Ninety‐one BCS participated, among whom 25.3% presented neuropathic pain, 18.7% nociceptive pain, and 15.4% CS pain. Mixed pain was found in 40.6%. A significant intergroup difference in HRQoL was found for SF‐36 “general health” (P = 0.04). The odds for the presence of CS rather than nociceptive pain are 26 times higher in patients exposed to hormone therapy in comparison to the nonexposed (odds ratio 25.95, 95% confidence interval 1.33 to 504.37, P = 0.03). Conclusion Neuropathic pain is most frequent in BCS. Strong associations were found between CS pain and hormone therapy.

show abstract

“…In 2014, the number of new cases of breast cancer in China accounted for 12.2% of the new cases worldwide, and the number of mortalities due to breast cancer accounted for ~9.6% of the number mortalities due to breast cancer worldwide (10). At present, the major treatment modalities for breast cancer include surgical resection, chemotherapy, radiotherapy and biological therapy (11,12). Patients with non-TNBC have a better prognosis when diagnosed and treated early (13); however, TNBC is characterized by an early age of onset, high degree of malignancy, high recurrence rate, early metastasis and poor prognosis (14).…”

Section: Discussionmentioning

confidence: 99%

Downregulation of RIP140 in triple‑negative breast cancer inhibits the growth and proliferation of cancer cells

Yu¹,

Xue²,

Zhu

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

The aim of the present study was to investigate the expression of receptor interacting protein 140 (RIP140) in triple-negative breast cancer (TNBC), and its association with the prognosis of patients with TNBC. A total of 179 patients with breast cancer were included in this study, with 41 cases of TNBC and 138 cases of non-TNBC. Immunohistochemical staining and western blotting were used to detect the protein expression of RIP140 in the cancerous and paracancerous tissues, revealing that expression of RIP140 was increased in TNBC tissues compared with non-TNBC tissues. High expression of RIP140 in breast cancer tissue was associated with a poorer survival time than low RIP140 expression. Using lentiviral transfection to downregulate RIP140 expression in MDA-MB-231 cells, the effects of RIP140 on the growth and proliferation of breast cancer cells was analyzed using subcutaneous tumors in BALB/c nude mice. Immunohistochemical staining using a Ki-67 antibody in subcutaneous tumor tissue was used to assess the proliferation of MDA-MB-231 cells. The short hairpin RNA-mediated downregulation of RIP140 in MDA-MB-231 cells suppressed the growth and the proliferation of subcutaneous tumors in BALB/c nude mice. Downregulation of RIP140 in breast cancer cells may therefore inhibit the growth and the proliferation of these cells, and may provide a therapeutic target for TNBC.

show abstract

Prevalence and risk factors associated with pain 21 months following surgery for breast cancer

Abstract: Pain is a significant problem following breast cancer treatment in both the early post-operative period and months following surgery. Risk factors for pain at long-term follow-up included arm symptoms and higher emotional subscale scores at baseline.

Cited by 25 publications

References 38 publications

Comparison of the efficacy of erector spinae plane block performed with different concentrations of bupivacaine on postoperative analgesia after mastectomy surgery: ramdomized, prospective, double blinded trial

Comparison of the efficacy of erector spinae plane block performed with different concentrations of bupivacaine on postoperative analgesia after mastectomy surgery: ramdomized, prospective, double blinded trial

Chronic Pain in Breast Cancer Survivors: Nociceptive, Neuropathic, or Central Sensitization Pain?

Downregulation of RIP140 in triple‑negative breast cancer inhibits the growth and proliferation of cancer cells

Contact Info

Product

Resources

About